1
|
Sarogni P, Frusca V, Zamborlin A, Giannini N, Menicagli M, Brancato L, Linsalata S, Di Martino F, Gonnelli A, Paiar F, Van den Bossche J, Bogers J, Voliani V. Neoadjuvant Hyperthermia Combined with Hybrid Nanoarchitectures Enhances Chemoradiotherapy Efficacy in Head and Neck Carcinoma. ACS APPLIED MATERIALS & INTERFACES 2024; 16:43272-43282. [PMID: 39126693 DOI: 10.1021/acsami.4c07393] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 08/12/2024]
Abstract
Head and neck squamous cell carcinomas are characterized by a high incidence of recurrence, especially in patients with locally advanced disease. Standard treatment strategies can be associated with severe side effects to healthy tissues that can negatively impact the patient's quality of life. Hyperthermia (HT) is a noninvasive treatment modality that has improved the effectiveness of chemotherapy (CT) and/or radiotherapy (RT) for the management of some solid neoplasms. In this context, the association of this approach with rationally designed nanomaterials may further enhance the treatment outcome. In this study, we demonstrate the enhanced effect of neoadjuvant HT in combination with hybrid nanoarchitectures enclosing a cisplatin prodrug (NAs-CisPt) and RT. All the treatments and their combinations have been fully evaluated by employing standardized chorioallantoic membrane tumor models of HPV-negative head and neck carcinoma. An improved tumor-shrinking effect was observed by the administration of the trimodal treatment (HT/NAs-CisPt/RT), which also highlighted a significant increase in apoptosis. Our findings demonstrate that the combination of HT with nanotechnology-based CT and RT in a certain order enhances the in vivo treatment outcome. On a broader basis, this study paves the way for the next exploration of noninvasive treatment approaches for the clinical management of oral cancer based on innovative strategies.
Collapse
Affiliation(s)
- Patrizia Sarogni
- Center for Nanotechnology Innovation@NEST, Istituto Italiano di Tecnologia, Piazza San Silvestro 12, 56127 Pisa, Italy
| | - Valentina Frusca
- Center for Nanotechnology Innovation@NEST, Istituto Italiano di Tecnologia, Piazza San Silvestro 12, 56127 Pisa, Italy
- Scuola Superiore Sant'Anna, Piazza Martiri della Libertà 33, 56127 Pisa, Italy
| | - Agata Zamborlin
- Center for Nanotechnology Innovation@NEST, Istituto Italiano di Tecnologia, Piazza San Silvestro 12, 56127 Pisa, Italy
- NEST-Scuola Normale Superiore, Piazza San Silvestro 12, 56127 Pisa, Italy
| | - Noemi Giannini
- Center for Nanotechnology Innovation@NEST, Istituto Italiano di Tecnologia, Piazza San Silvestro 12, 56127 Pisa, Italy
- Radiation Oncology Unit, Pisa University Hospital "Azienda Ospedaliero-Universitaria Pisana", Via Roma 67, 56126 Pisa, Italy
| | - Michele Menicagli
- Fondazione Pisana per la Scienza ONLUS, via Ferruccio Giovannini 13, S. Giuliano Terme, 56017 Pisa, Italy
| | | | - Stefania Linsalata
- Unit of Medical Physics, Pisa University Hospital "Azienda Ospedaliero-Universitaria Pisana", Via Roma 67, 56126 Pisa, Italy
| | - Fabio Di Martino
- Unit of Medical Physics, Pisa University Hospital "Azienda Ospedaliero-Universitaria Pisana", Via Roma 67, 56126 Pisa, Italy
| | - Alessandra Gonnelli
- Center for Nanotechnology Innovation@NEST, Istituto Italiano di Tecnologia, Piazza San Silvestro 12, 56127 Pisa, Italy
- Radiation Oncology Unit, Pisa University Hospital "Azienda Ospedaliero-Universitaria Pisana", Via Roma 67, 56126 Pisa, Italy
| | - Fabiola Paiar
- Radiation Oncology Unit, Pisa University Hospital "Azienda Ospedaliero-Universitaria Pisana", Via Roma 67, 56126 Pisa, Italy
| | | | - Johannes Bogers
- ElmediX NV, Esperantolaan 4, 3001 Heverlee, Belgium
- Laboratory of Cell Biology and Histology, University of Antwerp, 2610 Antwerp, Belgium
| | - Valerio Voliani
- Center for Nanotechnology Innovation@NEST, Istituto Italiano di Tecnologia, Piazza San Silvestro 12, 56127 Pisa, Italy
- Department of Pharmacy, School of Medical and Pharmaceutical Sciences, University of Genoa, Viale Cembrano, 4, 16148 Genoa, Italy
| |
Collapse
|
2
|
Maurici CE, Colenbier R, Wylleman B, Brancato L, van Zwol E, Van den Bossche J, Timmermans JP, Giovannetti E, Mori da Cunha MGMC, Bogers J. Hyperthermia Enhances Efficacy of Chemotherapeutic Agents in Pancreatic Cancer Cell Lines. Biomolecules 2022; 12:651. [PMID: 35625581 PMCID: PMC9138677 DOI: 10.3390/biom12050651] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2022] [Revised: 04/21/2022] [Accepted: 04/26/2022] [Indexed: 02/01/2023] Open
Abstract
Chemotherapy (CT) is the standard care for advanced pancreatic ductal adenocarcinoma (PDAC); however, with limited efficacy. Hyperthermia (HT) treatment has been suggested as a sensitizer to improve outcomes. However, the direct effect of the HT and CT combination is not fully understood. Therefore, we aim to assess the direct cytotoxic effect of HT in PDAC cells as monotherapy or in combination with chemotherapeutics. Different temperatures (37-, 40.5-, 41-, and 41.5 °C) and durations (6-, 12-, and 24 h) were tested in PDAC cell lines (BxPC-3, Capan-1, Capan-2, PANC-1, and MIA-PaCa-2). Different concentrations of gemcitabine, 5-fluorouracil, and cisplatin were also tested in these conditions. The impact on cell metabolic activity was determined by an MTS assay. Enhancement of chemosensitivity was assessed by a reduction in half-maximal inhibitory concentration (IC50). HT and chemotherapeutics interactions were classified as antagonistic, additive, or synergistic using the combination index. HT inhibited cell proliferation in a cell type, temperature, and duration-dependent manner. The induction of apoptosis was seen after 6 h of HT treatment, eventually followed by secondary necrosis. The HT and CT combination led to an IC50 reduction of the tested CT. At 12 h of HT, this effect was between 25 to 90% and reached a 95% reduction at 24 h. The additive or synergistic effect was demonstrated in all cell lines and chemotherapeutics, although, again, this depended on cell type, duration, and temperature. HT is cytotoxic and enhances the therapeutic effectiveness of gemcitabine, 5-fluorouracil, and cisplatin on PDAC cells. This result was further confirmed by the decrease in the expression of RRM2, TS, and ERCC1 in BxPC-3 and Capan-2 cells. These observations warrant further study in specific subsets of PDAC patients to improve their clinical outcomes.
Collapse
Affiliation(s)
- Costanza E. Maurici
- ElmediX NV, 2800 Mechelen, Belgium; (C.E.M.); (B.W.); (L.B.); (E.v.Z.); (J.V.d.B.); (M.G.M.C.M.d.C.)
| | - Robin Colenbier
- Laboratory of Cell Biology and Histology, Faculty of Medicine and Health Sciences, University of Antwerp, 2610 Antwerp, Belgium; (R.C.); (J.-P.T.)
- Cancer Center Amsterdam, Department of Medical Oncology, Amsterdam UMC, 1006 Amsterdam, The Netherlands;
| | - Britta Wylleman
- ElmediX NV, 2800 Mechelen, Belgium; (C.E.M.); (B.W.); (L.B.); (E.v.Z.); (J.V.d.B.); (M.G.M.C.M.d.C.)
| | - Luigi Brancato
- ElmediX NV, 2800 Mechelen, Belgium; (C.E.M.); (B.W.); (L.B.); (E.v.Z.); (J.V.d.B.); (M.G.M.C.M.d.C.)
| | - Eke van Zwol
- ElmediX NV, 2800 Mechelen, Belgium; (C.E.M.); (B.W.); (L.B.); (E.v.Z.); (J.V.d.B.); (M.G.M.C.M.d.C.)
| | - Johan Van den Bossche
- ElmediX NV, 2800 Mechelen, Belgium; (C.E.M.); (B.W.); (L.B.); (E.v.Z.); (J.V.d.B.); (M.G.M.C.M.d.C.)
| | - Jean-Pierre Timmermans
- Laboratory of Cell Biology and Histology, Faculty of Medicine and Health Sciences, University of Antwerp, 2610 Antwerp, Belgium; (R.C.); (J.-P.T.)
| | - Elisa Giovannetti
- Cancer Center Amsterdam, Department of Medical Oncology, Amsterdam UMC, 1006 Amsterdam, The Netherlands;
- Cancer Pharmacology Lab, Fondazione Pisana per la Scienza, 56017 Pisa, Italy
| | | | - Johannes Bogers
- ElmediX NV, 2800 Mechelen, Belgium; (C.E.M.); (B.W.); (L.B.); (E.v.Z.); (J.V.d.B.); (M.G.M.C.M.d.C.)
- Laboratory of Cell Biology and Histology, Faculty of Medicine and Health Sciences, University of Antwerp, 2610 Antwerp, Belgium; (R.C.); (J.-P.T.)
- Applied Molecular Biology Research Group (AMBIOR), University of Antwerp, 2610 Antwerp, Belgium
| |
Collapse
|
3
|
Zheng S, Zhou C, Jiang X, Huang J, Xu D. Progress on Infrared Imaging Technology in Animal Production: A Review. SENSORS 2022; 22:s22030705. [PMID: 35161450 PMCID: PMC8839879 DOI: 10.3390/s22030705] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 11/07/2021] [Revised: 12/28/2021] [Accepted: 01/13/2022] [Indexed: 02/01/2023]
Abstract
Infrared thermography (IRT) imaging technology, as a convenient, efficient, and contactless temperature measurement technology, has been widely applied to animal production. In this review, we systematically summarized the principles and influencing parameters of IRT imaging technology. In addition, we also summed up recent advances of IRT imaging technology in monitoring the temperature of animal surfaces and core anatomical areas, diagnosing early disease and inflammation, monitoring animal stress levels, identifying estrus and ovulation, and diagnosing pregnancy and animal welfare. Finally, we made prospective forecast for future research directions, offering more theoretical references for related research in this field.
Collapse
Affiliation(s)
- Shuailong Zheng
- Key Laboratory of Swine Genetics and Breeding, Ministry of Agriculture and Rural Affairs, Huazhong Agricultural University, Wuhan 430070, China; (S.Z.); (C.Z.)
- Key Laboratory of Agricultural Animal Genetics, Breeding and Reproduction of Ministry of Education, Huazhong Agricultural University, Wuhan 430070, China;
- Colleges of Animal Science & Technology, Huazhong Agricultural University, Wuhan 430070, China
| | - Changfan Zhou
- Key Laboratory of Swine Genetics and Breeding, Ministry of Agriculture and Rural Affairs, Huazhong Agricultural University, Wuhan 430070, China; (S.Z.); (C.Z.)
- Key Laboratory of Agricultural Animal Genetics, Breeding and Reproduction of Ministry of Education, Huazhong Agricultural University, Wuhan 430070, China;
- Colleges of Animal Science & Technology, Huazhong Agricultural University, Wuhan 430070, China
| | - Xunping Jiang
- Key Laboratory of Agricultural Animal Genetics, Breeding and Reproduction of Ministry of Education, Huazhong Agricultural University, Wuhan 430070, China;
- Colleges of Animal Science & Technology, Huazhong Agricultural University, Wuhan 430070, China
| | - Jingshu Huang
- Agricultural Development Center of Hubei Province, Wuhan 430064, China;
| | - Dequan Xu
- Key Laboratory of Swine Genetics and Breeding, Ministry of Agriculture and Rural Affairs, Huazhong Agricultural University, Wuhan 430070, China; (S.Z.); (C.Z.)
- Key Laboratory of Agricultural Animal Genetics, Breeding and Reproduction of Ministry of Education, Huazhong Agricultural University, Wuhan 430070, China;
- Colleges of Animal Science & Technology, Huazhong Agricultural University, Wuhan 430070, China
- Correspondence:
| |
Collapse
|
4
|
Wylleman B, Brancato L, Gorbaslieva I, van Zwol E, Mori da Cunha MGMC, Benoit J, Tierny D, Vueghs P, Van den Bossche J, Rudenko O, Janicot M, Bogers J. Tolerability of long-term temperature controlled whole-body thermal treatment in advanced cancer-bearing dogs. Int J Hyperthermia 2021; 39:48-56. [PMID: 34937522 DOI: 10.1080/02656736.2021.2000649] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
Abstract
Aim: In oncology, thermal therapy is the application of external heat to fight cancer cells. The goal of whole-body thermal treatment (WBTT) is to raise the patient's core temperature to 39-42 °C, and represents the only thermal treatment modality that can act on both the primary tumor and distant metastases. However, WBTT carries potential risks for toxicity when applied without accurate thermometry and monitoring.Methods: ElmediX has developed a medical device, HyperTherm, to deliver long-term controlled and accurate WBTT (41.5 °C, up to 8 h). The safety of the device and thermal treatment protocol was initially evaluated in minipigs, and we present the confirmation of tolerability of WBTT in dogs with advanced cancer, in combination with a reduced dose of radiotherapy or chemotherapy.Results: Thermometry in liver, rectum, and tumor confirmed a homogeneous heating of these body parts. Monitoring of clinical parameters showed acceptable and reversible changes in liver, cardiac, muscle and coagulation parameters, as was expected. Combination of WBTT with both radiotherapy and chemotherapy only caused some low-grade adverse events.Conclusion: We conclude that our findings support the safe use of HyperTherm-mediated WBTT for canine patients with advanced malignancies. They also tend to support a genuine therapeutic potential for long-term WBTT which needs to be confirmed on a larger dog patient population. Combined with previously reported safety results in minipigs, these contribute to support the ongoing clinical evaluation of WBTT in advanced human cancer patients.
Collapse
Affiliation(s)
| | | | | | | | | | - J Benoit
- Oncovet - Veterinary Cancer Center, Villeneuve-d'Ascq, France
| | - D Tierny
- Oncovet Clinical Research (OCR), Loos, France
| | | | | | | | | | - J Bogers
- ElmediX NV, Mechelen, Belgium.,Laboratory of Cell Biology and Histology, University of Antwerp, Belgium
| |
Collapse
|